Biotech Startups

Germfree provides cleanroom and biocontainment facility solutions for pharmaceutical, pharmacy, and biopharma manufacturing, leveraging over 60 years of experience and in-house fabrication technology. The company serves life science organizations developing medicines and conducting research requiring controlled laboratory environments.

1 investor

Gero is a biotech company applying AI, data science, and physics-based models of human health to discover drug targets and therapies for aging and age-related chronic diseases. It develops a therapeutic pipeline using longitudinal health data, statistical genetics, and multi-omics.

1 investor

Culturewell provides environmental microbiology testing and germ detection services to healthcare facilities for identifying contamination and preventing healthcare-associated infections. The service uses proprietary sampling methods, laboratory analysis, and AI-driven risk assessment to deliver actionable insights on cleaning compliance and outbreak prevention.

1 investor

GEXVal is a pharmaceutical company focused on researching and developing medicines for difficult-to-treat and rare diseases. The company is based in Japan with operations including a subsidiary in Australia.

1 investor

GFBiochemicals develops plant-based chemical ingredients derived from levulinate technology to replace harmful petrochemical components in consumer products such as shampoos, detergents, and cosmetics. The company operates manufacturing and research facilities across Europe and Asia, targeting reduction of carbon emissions and chemical pollution in everyday household and personal care products.

1 investor

GFC Life Science (지에프씨생명과학) develops cosmetic ingredients based on skin microbiome research and plant cell cultivation, including exosome and miRNA-based materials from its proprietary strain library. Its clinical division conducts dermatologist-led safety and efficacy testing for cosmetics, including regulatory evaluations for wrinkles, whitening, and hair loss.

1 investor

GHO Capital is a venture capital firm focused on healthcare innovation, specifically supporting pharmaceutical and biotechnology companies with product development and manufacturing solutions.

1 investor

Ghoonuts conducts research and development using transcranial electrical stimulation technology. The company appears to focus on neuroscience applications, with involvement in clinical neurophysiology and VR domains.

1 investor

GIE Medical is a clinical-stage medical device company developing the ProTractX3, a drug-coated balloon for treating benign strictures of the esophagus and bowel. It is conducting clinical trials in the United States aimed at offering gastroenterology patients sustained patency and fewer repeat treatments.

1 investor

GigaCrop develops engineered crops with improved photosynthesis to increase agricultural yields for food, fiber, and fuel production. The company uses synthetic biology and enzyme engineering to enhance plant productivity sustainably.

1 investor

GIVAX is a biotechnology company focused on vaccine development. The company's board includes scientific expertise in virology and venture capital backing from leading biotech investors.

1 investor

Glaukos develops micro-scale medical devices and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, replacing traditional drop therapies with minimally invasive surgery platforms. Founded in 1998 and publicly traded on the NYSE, the company serves ophthalmology patients globally.

1 investor

Glenclova Scientific develops a virus-like particle (VLP) platform that displays therapeutic proteins and peptides to enhance the efficacy and reduce the dosage requirements of biologic drugs. The platform targets chronic disease treatments, particularly for inflammatory, respiratory, dermatological, and oncological indications, with a focus on improved accessibility and affordability for resource-limited healthcare settings.

1 investor

GlioCART develops a dual-action CAR-T cell therapy for glioblastoma that targets tumor cells while reprogramming tumor-supporting myeloid cells into active immune effectors. The company aims to extend CAR-T therapy to solid tumors and other myeloid-driven cancers.

1 investor

1 investor

Global Cord Blood Corporation is China's leading provider of umbilical cord blood collection, laboratory testing, and hematopoietic stem cell processing and storage services. The company operates as a specialized biobank serving patients and families seeking cord blood banking and stem cell therapies.

1 investor

Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.

1 investor

GlycoSpot develops enzyme testing technology that enables rapid quality control of enzyme activity for industrial bioprocess applications. The platform helps industries transition to bio-based production processes by providing quick, cost-effective measurement solutions without requiring specialized expertise.

1 investor

Glycotest develops diagnostic tests for the early detection of liver disease and liver cancer. The company operates in the biomedical diagnostics field within the healthcare industry.

1 investor

Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.

1 investor

Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. Its approach originated from research on how certain bariatric surgeries improve glucose and metabolic regulation and produce sustained weight loss.

1 investor

Gnomica develops small-molecule drug inhibitors that target bacterial pathways as a treatment for cancer.

1 investor

GoodCap Pharmaceuticals develops drug candidates targeting disorders driven by neuroinflammation, with a lead candidate (GCAP001) combining two molecule classes to reduce inflammatory biomarkers linked to psychiatric and neurodegenerative conditions. Its initial focus is on treating PTSD.

1 investor

Goodfellow supplies advanced specialist materials, including metals, alloys, ceramics, polymers, and compounds, alongside custom manufacturing and modification services for scientific and industrial customers worldwide. The company also provides micromanufacturing capabilities through its 2024 acquisition of Potomac Photonics.

1 investor